Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

Table 1

Patient characteristics.

	Number of patients
Sex
Male	22
Female	2
Age (median)	63 (49–73)
Performance status (ECOG)
0	9
1	12
2	3
Histology
Intestinal	16
Diffuse	8
Site of metastasis
Lymph nodes	22
Liver	14
Peritoneum	10
Lung	6
Prior chemotherapy
S-1+cisplatin	15
S-1+cisplatin+docetaxel	8
5-FU+cisplatin+radiation therapy	1

ECOG, Eastern Cooperative Oncology Group; S-1, tegafur, gimeracil, oteracil potassium; 5-FU, 5-fluorouracil.